

Figure S1




Figure S1. PTEN gene mutations in GBM cells and its impact on drug sensitivities of PI3K inhibitors. (A) Mutations of four essential GBM oncogenes or tumor suppressor genes in eight GBM cell lines. (B) Antiproliferation rate of LN18, LN18 sgRNA negative control, LN18 PTEN knockout #1 and 2 cell lines upon treatment of BKM120. (C) PTEN expression in PI3K inhibitor sensitive, intermediate sensitive or resistant cell lines collection. GSK1059615 is a dual inhibitor of pan-class I PI3K and mTOR kinase. (D) Linear regression of PTEN protein levels and BKM120 sensitivity demonstrated a strong correlative trend in terms of R and p values by Spearman's rank correlation test ($p=0.0256$). Data of C and D were obtained from public database (Wooster dataset and Oncomine database).